XML 118 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the years 2019, 2018 and 2017 were as follows:
(in millions)
2019
 
2018
 
2017
Revenues:
 
 
 
 
 
Bausch + Lomb/International
$
4,739

 
$
4,664

 
$
4,795

Salix
2,022

 
1,749

 
1,566

Ortho Dermatologics
565

 
617

 
721

Diversified Products
1,275

 
1,350

 
1,642

Total revenues
$
8,601

 
$
8,380

 
$
8,724

Segment profit:
 
 
 
 
 
Bausch + Lomb/International
$
1,332

 
$
1,330

 
$
1,412

Salix
1,349

 
1,149

 
935

Ortho Dermatologics
222

 
257

 
333

Diversified Products
932

 
1,012

 
1,115

Total segment profit
3,835

 
3,748

 
3,795

Corporate
(609
)
 
(605
)
 
(562
)
Amortization of intangible assets
(1,897
)
 
(2,644
)
 
(2,690
)
Goodwill impairments

 
(2,322
)
 
(312
)
Asset impairments
(75
)
 
(568
)
 
(714
)
Restructuring and integration costs
(31
)
 
(22
)
 
(52
)
Acquisition-related contingent consideration
(12
)
 
9

 
289

Other expense (income), net
(1,414
)
 
20

 
348

Operating (loss) income
(203
)
 
(2,384
)
 
102

Interest income
12

 
11

 
12

Interest expense
(1,612
)
 
(1,685
)
 
(1,840
)
Loss on extinguishment of debt
(42
)
 
(119
)
 
(122
)
Foreign exchange and other
8

 
23

 
107

Loss before benefit from income taxes
$
(1,837
)
 
$
(4,154
)
 
$
(1,741
)

Schedule of capital expenditures, depreciation and amortization by segment
Capital expenditures by segment for the years 2019, 2018 and 2017 were as follows:
(in millions)
2019
 
2018
 
2017
Capital expenditures:
 
 
 
 
 
Bausch + Lomb/International
$
225

 
$
139

 
$
159

Salix
2

 
2

 
3

Ortho Dermatologics
1

 
1

 
2

Diversified Products
2

 
2

 
4

 
230

 
144

 
168

Corporate
40

 
13

 
3

Total capital expenditures
$
270

 
$
157

 
$
171


Schedule of revenues by product and by product category Revenues by segment and product category were as follows:
(in millions)
Bausch + Lomb/ International
 
Salix
 
Ortho Dermatologics
 
Diversified Products
 
Total
 
2019
2018
2017
 
2019
2018
2017
 
2019
2018
2017
 
2019
2018
2017
 
2019
2018
2017
Pharmaceuticals
$
885

$
892

$
956

 
$
2,022

$
1,752

$
1,564

 
$
355

$
457

$
567

 
$
810

$
927

$
1,290

 
$
4,072

$
4,028

$
4,377

Devices
1,524

1,505

1,421

 



 
193

135

111

 



 
1,717

1,640

1,532

OTC
1,452

1,412

1,529

 



 



 



 
1,452

1,412

1,529

Branded and Other Generics
801

784

819

 



 



 
447

407

338

 
1,248

1,191

1,157

Other revenues
77

71

70

 

(3
)
2

 
17

25

43

 
18

16

14

 
112

109

129

 
$
4,739

$
4,664

$
4,795

 
$
2,022

$
1,749

$
1,566

 
$
565

$
617

$
721

 
$
1,275

$
1,350

$
1,642

 
$
8,601

$
8,380

$
8,724


Schedule of revenues and long-lived assets by geographic region
Revenues are attributed to a geographic region based on the location of the customer for the years 2019, 2018 and 2017 were as follows:
(in millions)
2019
 
2018
 
2017
U.S. and Puerto Rico
$
5,164

 
$
5,011

 
$
5,225

China
368

 
361

 
331

Canada
339

 
319

 
326

Japan
241

 
226

 
223

Poland
231

 
218

 
201

Mexico
228

 
211

 
201

Egypt
218

 
178

 
152

France
201

 
205

 
188

Russia
180

 
154

 
200

Germany
150

 
170

 
157

United Kingdom
115

 
117

 
108

Spain
86

 
83

 
77

Italy
85

 
85

 
78

Other
995

 
1,042

 
1,257

 
$
8,601

 
$
8,380

 
$
8,724


Schedule of assets by geographic region
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2019 and 2018 were as follows:
(in millions)
2019
 
2018
U.S. and Puerto Rico
$
656

 
$
593

Ireland
255

 
217

Canada
103

 
99

Poland
90

 
94

Germany
68

 
66

Egypt
62

 
50

Mexico
50

 
48

France
30

 
31

China
27

 
25

Serbia
27

 
28

Italy
22

 
23

Other
76

 
79

 
$
1,466

 
$
1,353


Schedule of external customers that accounted for 10% or more of total revenues
Customers that accounted for 10% or more of total revenues were as follows:

2019
 
2018
 
2017
McKesson Corporation
17%

18%

19%
AmerisourceBergen Corporation
16%

18%

15%
Cardinal Health, Inc.
14%

13%

13%